ReviewAdvances in therapy2025

Efficacy, Safety, and Immunogenicity of SDZ-ADL, an Adalimumab Biosimilar, in Biologic-Naïve and Switched Patients with Immune-Mediated Inflammatory Diseases: A Literature Review.

Piotr Wiland et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.